IP Library › Granted Patent US 12,697,341
Granted Patent B1
US 12,697,341 · App. 19/397,383 · Granted Aug 4, 2026

Methods of using meloxicam for pain treatment and management

Inventors: Susanne Vogt (Bad Homburg v.d. Höhe, DE); Jeffrey P. Smith (Morgantown, WV); Kathleen Ocasio (Morgantown, WV); Joachim Maus (Hanau, DE); Kristina Marschall (Bad Homburg v.d. Höhe, DE); Matthew Hummel (Beaver, PA); Scott Haughie (Kent, GB); Abhijit Deshmukh (Hyderabad, IN); Amit Antarkar (Hyderabad, IN)
Assignee: Viatris Inc.
A61K31/5415A61K9/0053A61K9/2009A61K9/2027A61K9/2054A61K9/2077A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,697,341
App. No.
19/397,383
Filed
Nov 21, 2025
Granted
Aug 4, 2026
Kind
B1
Art Unit
1691
USPC
514/226.5
Abstract

The present invention relates to a method for managing pain, such as acute pain, post-operative pain, or post-procedure pain, by administering meloxicam.

Claims (29)

1 . A method of treating moderate to severe pain in an individual in need thereof comprising administering a solid oral meloxicam composition to the individual, wherein the composition comprises an amount of meloxicam or a pharmaceutically acceptable meloxicam salt equivalent to 15 mg meloxicam, the individual's pain before administration of the composition is at a level the same as an adult human reporting a pain level of about from 4.0 to about 10.0 on a pain NRS, and the time to the individual's first meaningful pain relief is about 5.5 hours or less following administration of the composition.

2 . The method of claim 1 wherein the time to the individual's first meaningful pain relief is between about 2 hours to about 5.5 hours following administration of the composition.

3 . The method of claim 2 wherein the time to the first meaningful pain relief is between about 2.4 hours and 3.7 hours following administration of the composition.

4 . The method of claim 1 wherein the pain before administration of the composition is severe and is at a level the same as an adult human reporting a pain level of about 7.0 to about 10.0 on a pain NRS.

5 . The method of claim 1 wherein the pain before administration of the composition is moderate and is at a level the same as an adult human reporting a pain level of from about 4.0 to about 6.0 on a pain NRS.

6 . The method of claim 1 wherein the composition is administered to the individual about every 12 hours and wherein the individual's pain level decreases for about 48 hours after a first administration of the composition.

7 . The method of claim 1 wherein the pain comprises acute pain.

8 . The method of claim 1 wherein the pain comprises procedural pain.

9 . The method of claim 8 wherein the individual has undergone a surgery.

10 . The method of claim 1 wherein the composition is administered to the individual without food or when the individual is in a semi-fasted state.

11 . The method of claim 1 wherein the composition is administered to the individual about every 12 hours for 30 days or less.

12 . The method of claim 11 wherein the composition is administered to the individual about every 12 hours for 7 days or less.

13 . The method of claim 12 wherein the composition is administered four times to the individual about every 12 hours for 2 days (48 hours) or less.

14 . The method of claim 12 wherein the treatment is without significant risk to the individual of a gastrointestinal bleeding adverse event.

15 . The method of claim 12 wherein the treatment is without significant risk to the individual of a cardiovascular event.

16 . The method of claim 1 wherein the individual exhibits opioid-sparing behavior after administration of the composition.

17 . The method of claim 16 wherein the individual does not receive an opioid analgesic for at least about 48 hours after administration of the composition.

18 . The method of claim 1 wherein the individual does not receive a rescue pain medication before experiencing meaningful pain relief following administration of the composition.

19 . The method of claim 1 wherein the meloxicam or pharmaceutically acceptable meloxicam salt is in alkaline surroundings in the composition.

20 . The method of claim 1 wherein the composition comprises one or more alkalizing agents and one or more hydrophilic polymers.

21 . The method of claim 1 wherein the composition comprises sodium bicarbonate and an excipient selected from copovidone, hypromellose, or a combination of copovidone and hypromellose.

22 . The method of claim 21 comprising granules or pellets of meloxicam.

23 . A method of treating moderate to severe pain in an individual in need thereof comprising administering a solid oral meloxicam composition to the individual, wherein the composition comprises 15 mg of meloxicam, and wherein the individual's pain about 48 hours from the time of administration of the composition is relieved by a degree corresponding to a 48-hour summed pain intensity difference (SPID 0-48 ) of from about 163.0 to about 204.7 or from about 145.5 to about 180.7 using an 11-point NRS (zero to 10) for pain intensity.

24 . The method of claim 23 , wherein the individual feels pain at the time of administration of the composition at a level corresponding to about from 4.0 to about 10.0 using an 11-point NRS (zero to 10) for pain intensity.

25 . The method of claim 24 , wherein the composition is in the form of a tablet or tablets.

26 . A method of treating moderate to severe pain in an individual in need thereof comprising administering a solid oral meloxicam composition to the individual, wherein the composition comprises 15 mg of meloxicam, and wherein the composition provides a least squares mean summed pain intensity difference over 48 hours (least squares mean SPID 0-48 ) using an 11-point pain NRS (zero to 10) in a population of clinical study subjects of from about 163.0 to about 204.7 or from about 145.5 to about 180.7.

27 . The method of claim 26 wherein the individual feels pain around the time of administration of the composition at a level corresponding to about from 4.0 to about 10.0 on an 11-point pain NRS (zero to 10).

28 . The method of claim 26 wherein the composition is in the form of a tablet or tablets.

29 . The method of claim 27 wherein the composition is in the form of a tablet or tablets.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2026
From: VOGT, SUSANNE; DESHMUKH, ABHIJIT; ANTARKAR, AMIT; HAUGHIE, SCOTT; SMITH, JEFFREY P.; OCASIO, KATHLEEN; MAUS, JOACHIM; MARSCHALL, KRISTINA; HUMMEL, MATTHEW
To: VIATRIS INC.
Reel/Frame 074116/0863 →
Continuity (4)
Provisional Application 63862494 · Aug 12, 2025
Provisional Application 63821323 · Jun 10, 2025
Provisional Application 63802518 · May 8, 2025
Provisional Application 63801585 · May 7, 2025
References Cited (121)
US 9526734B2 · Bosch · 2016 [cited by applicant]
US 9649318B2 · Bosch · 2017 [cited by applicant]
US 9808468B2 · Bosch · 2017 [cited by applicant]
US 9821075B2 · Tabuteau · 2017 [cited by applicant]
US 10265399B2 · Tabuteau · 2019 [cited by applicant]
US 10265400B2 · Tabuteau · 2019 [cited by applicant]
US 10307484B2 · Tabuteau · 2019 [cited by applicant]
US 10369224B2 · Tabuteau · 2019 [cited by applicant]
US 10369225B2 · Tabuteau · 2019 [cited by applicant]
US 10426839B2 · Tabuteau · 2019 [cited by applicant]
US 10463736B2 · Tabuteau · 2019 [cited by applicant]
US 10709713B2 · Cooper et al. · 2020 [cited by applicant]
US 20050053669A1 · Friedl et al. · 2005 [cited by applicant]
US 20070077296A1 · Folger et al. · 2007 [cited by applicant]
US 20110160273A1 · Buschmann et al. · 2011 [cited by applicant]
US 20110212948A1 · Pippia · 2011 [cited by examiner]
US 20120149692A1 · Hanna et al. · 2012 [cited by applicant]
US 20130224151A1 · Pearson et al. · 2013 [cited by applicant]
US 20170281640A1 · Romero Medina et al. · 2017 [cited by applicant]
US 20200085835A1 · Bosch · 2020 [cited by applicant]
US 20220184095A1 · Allan et al. · 2022 [cited by applicant]
US 20230172943A1 · Allan et al. · 2023 [cited by applicant]
US 20240277726A1 · Patil et al. · 2024 [cited by applicant]
US 20250352478A1 · Patil et al. · 2025 [cited by applicant]
US 20250352479A1 · Patil et al. · 2025 [cited by applicant]
US 20250352552A1 · Patil et al. · 2025 [cited by applicant]
CA 2976272C · 2018 [cited by applicant]
CN 1233323C · 2005 [cited by applicant]
CN 107405359A · 2017 [cited by applicant]
CN 107970219A · 2018 [cited by applicant]
EP 4008319B1 · 2024 [cited by applicant]
JP 2011207875A · 2011 [cited by applicant]
JP 4965130B2 · 2012 [cited by applicant]
NZ 540226A · 2008 [cited by applicant]
WO WO2009094155A1 · 2009 [cited by applicant]
WO WO2011086194A1 · 2011 [cited by applicant]
WO WO2020219406A1 · 2020 [cited by applicant]
WO WO2020262618A1 · 2020 [cited by applicant]
WO WO2021216545A1 · 2021 [cited by applicant]
WO WO2022097024A1 · 2022 [cited by applicant]
Tacca et al. Clinical Drug Investigation, 2002, 22(12): 799-818. [cited by examiner]
Yocum et al. Archives of Internal Medicine, 2000, 160(19): 2947-2954. [cited by examiner]
Abass Met al, “Synergistic efficacy of tramadol and meloxicam on alleviation of pain and selected immunological variables after sciatic nerve ligation in rats”, Int J Vet Sci Med, 2014, 2(1):14-20. [cited by applicant]
Anjeso Package Insert, U.S. Food and Drug Administration, Revised Apr. 2021. [cited by applicant]
Auvinet et al., “Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients in acute sciatica”, Clin Ther, 17(6):1078-90, (1995). [cited by applicant]
Bittner, J.G., and Clingempeel, N.L. Hernia Repair in the United States: Current Situation and Trends. In: Campanelli, G. (eds) The Art of Hernia Surgery. 2018. Springer, Cham. [cited by applicant]
Blain H et al., Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin, (2002) 53(3):255-65. [cited by applicant]
Bourque S.L. et al., Comparison of buprenorphine and meloxicam for postsurgical analgesia in rats: effects on body weight, locomotor activity, and hemodynamic parameters. J Am Assoc Lab Anim Sci, (2010) 49 (5):617-622. [cited by applicant]
Breivik, H., et al., Assessment of pain. Br J Anaesth, 2008. 101(1): p. 17-24. [cited by applicant]
Bugada, D., et al., Effect of postoperative analgesia on acute and persistent postherniotomy pain: a randomized study. J Clin Anesth, 2015. 27(8): p. 658-664. [cited by applicant]
Burukoglu D et al., Effects of nonsteroidal anti-inflammatory meloxicam on stomach, kidney, and liver of rats. Toxicol Ind Health, (2016) 32:980-986. [cited by applicant]
Busch U et al. Pharmacokinetics of Meloxicam in Animals and the Relevance to Humans. Drug Metab Dispos, (1998) 26:576-584. [cited by applicant]
Cheung, C.W., et al., Oral Oxycodone for Acute Postoperative Pain: A Review of Clinical Trials. Pain Physician, 2017. 20(2S): p. SE33-SE52. [cited by applicant]
Chou, R., et al., Management of Postoperative Pain: a clinical practice guideline from the American pain society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologi… [cited by applicant]
Christensen, S.E., et al., A randomized double-blind controlled trial of intravenous meloxicam in the treatment of pain following dental impaction surgery. J Clin Pharm col. 2018. 58(5): p. 593-605. [cited by applicant]
Clinical Trial NCT04571515, Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain, https://clinicaltrials.gov/study/NCT04571515?term=NCT04571515&rank=1. [cited by applicant]
Clinical Trial NCT05317312, Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain, https://clinicaltrials.gov/study/NCT05317312?term=NCT05317312%20&rank=1. [cited by applicant]
Clinical Trial NCT06215820, Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy, https://clinicaltrials.gov/study/NCT06215820?term=NCT06215820&rank=1. [cited by applicant]
Clinical Trial NCT06215859, Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy, https://clinicaltrials.gov/study/NCT06215859?term=NCT06215859&rank=1. [cited by applicant]
ClinicalTrials.gov, “Evaluation of N1539 Following Bunionectomy Surgery”, Identifier NCT02675907, Last Updated Nov. 17, 2017. Accessed Oct. 31, 2025. Available at https://clinicaltrials.gov/study/NCT02675907#participati… [cited by applicant]
ClinicalTrials.gov. “Evaluation of N1539 Following Abdominoplasty Surgery.” Identifier NCT02678286, Last Updated Feb. 14, 2018. Accessed Oct. 31, 2025. Available at https://clinicaltrials.gov/study/NCT02678286#participa… [cited by applicant]
Co-pending U.S. Appl. No. 17/920,233, filed Oct. 20, 2022, published as US20230172943. [cited by applicant]
Co-pending U.S. Appl. No. 18/251,923, filed Nov. 3, 2021, published as US20240277726. [cited by applicant]
Co-pending U.S. Appl. No. 19/285,261, filed Jul. 30, 2025, published as US20250352478A1. [cited by applicant]
Co-pending U.S. Appl. No. 19/285,330, filed Jul. 30, 2025, published as US20250352552A1. [cited by applicant]
Co-pending U.S. Appl. No. 19/285,358, filed Jul. 30, 2025, published as US20250352479A1. [cited by applicant]
Co-pending U.S. Appl. No. 19/397,231, filed Nov. 21, 2025. [cited by applicant]
Co-pending U.S. Appl. No. 19/397,290, filed Nov. 21, 2025. [cited by applicant]
Co-pending U.S. Appl. No. 19/397,427, filed Nov. 21, 2025. [cited by applicant]
Combe et al., “Comparison of Intramuscular and Oral Meloxicam in Rheumatoid Arthritis Patients”, Inflammatory Research, 50(1):10-16, (2001). [cited by applicant]
Engelhardt et al., “Anti-inflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, A New Non-steroidal Anti-inflammatory Agent with Favourable Gastrointestinal Tolerance”, Inflamm Res, 1995, 44: 423-433. [cited by applicant]
Engelhardt et al., “General Pharmacology of Meloxicam—Part II: Effects on Blood Pressure, Blood Flow, Heart Rate, ECG, Respiratory Minute vol. and Interactions with Paracetamol, Pirenzepine, Chlorthalidone, Phenprocoumo… [cited by applicant]
Engelhardt et al., “Pharmacology of Meloxicam, A New Non-steroidal Anti-inflammatory Drug with An Improved Safety Profile Through Preferential Inhibition of COX-2”, British Journal Rheumatology, 35:4-12, (1996). [cited by applicant]
FDA Guidance for Industry: Multiple Endpoints in Clinical Trials. Oct. 2022. [cited by applicant]
FDA. Drug Safety Communication: FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use. Apr. 13, 2023. Accessed Oct. 28, 2025. Available at https://www.fda.gov/drug… [cited by applicant]
FDA. Guidance for Industry: Development of Non-Opioid Analgesics for Acute Pain. Feb. 2022. [cited by applicant]
FDA. Guidance for Industry: Development of Non-Opioid Analgesics for Chronic Pain. Sep. 2025. [cited by applicant]
FDA. Guidance for Industry: E8(R1) General Considerations for Clinical Studies. Apr. 2022. [cited by applicant]
Foroud M and Vesal N (2015). Evaluation of the anti-nociceptive effects of morphine, tramadol, meloxicam and their combinations using the tail-flick test in rats. In Veterinary Research Forum. 6:4, 313. [cited by applicant]
Gottlieb et al, “Evaluation of the Safety and Efficacy of an Intravenous Nanocrystal Formulation of Meloxicam in the Management of Moderate-to-severe Pain after Bunionectomy” Journal of Pain Research,16(11): p. 383-393,… [cited by applicant]
Hudgins, J.D., et al., Prescription opioid use and misuse among adolescents and young adults in the United States: A national survey study. PLoS Med, 2019. 16(11): p. e1002922. [cited by applicant]
Inal S et al. Comparison of the effects of dexketoprofen trometamol, meloxicam and diclofenac sodium on fibular fracture healing, kidney and liver: an experimental rat model. Injury, (2014) 45:494-500. [cited by applicant]
Isiordia-Espinoza et al, “Pre-emptive Analgesic Effectiveness of Meloxicam Versus Tramadol After Mandibular Third Molar Surgery: A Pilot Study”, J Oral Maxil Surg, 50 (1):31-36, (2012). [cited by applicant]
Karaca, Z. and McDermott, K.W., High-Volume Invasive, Therapeutic Ambulatory Surgeries Performed in Hospital-Owned Facilities, 2016. HCUP Statistical Brief #252. Sep. 2019. Agency for Healthcare Research and Quality, Ro… [cited by applicant]
Kehlet, H., Jensen, T.S., and Woolf, C.J., Persistent postsurgical pain: risk factors and prevention. Lancet, 2006. 367(9522): p. 1618-1625. [cited by applicant]
Kesaria, A.A., et al., Nationwide surgical trends for bunionectomies in medicare beneficiaries: An increase in lapidus bunionectomy procedure. Journal of Foot and Ankle Surgery, 2025. 64(5): p. 581-587. [cited by applicant]
Khalikov, S.P., et al., Inguinal Hernia: Prevalence, Risks, Treatment Prospects, American Journal of Medicine and Medical Sciences, 2024. 14(10): p. 2453-2457. [cited by applicant]
Khan, N.F., et al., Association ofOpioid Overdose With Opioid Prescriptions to Family Members. JAMA Intern Med, 2019. 179(9): p. 1186-1192. [cited by applicant]
Korwin-Kochanowska, K., et al., PROSPECT guideline for hallux valgus repair surgery: a systematic review and procedure-specific postoperative pain management recommendations. Reg Anesth Pain Med, 2020. 45: p. 702-708. [cited by applicant]
Kvarda, P., et al., Opioid consumption rate following foot and ankle surgery. Foot Ankle Orthop, 2019. 40(8): p. 905-913. [cited by applicant]
Maamar M, et al., Ibuprofen results in alterations of human fetal testis development. Scientific Reports, (2017) 7:1-15. [cited by applicant]
Martinez, V., et al., Chronic postsurgical pain: a European survey. Eur J Anaesthesiol, 2024. 41(5), p. 351-362. [cited by applicant]
McDermott, K.W. and Liang, L., Overview of Major Ambulatory Surgeries Performed in Hospital-Owned Facilities, 2019. HCUP Statistical Brief #287. Dec. 2021. Agency for Healthcare Research and Quality, Rockville, MD. Acce… [cited by applicant]
MOBIC Label (2024). Approved product labeling for MOBIC® (meloxicam) tablets, for oral use. USFDA. Boehringer Ingelheim Pharmaceuticals Inc. [cited by applicant]
Moeremans et al, “Pharmacokinetics and Absolute Oral Bioavailability of Meloxicam in Guinea Pigs ( [cited by applicant]
Moore, R.A., et al., Single dose oral analgesics for acute postoperative pain in adults—an overview of Cochrane reviews. Cochrane Database Syst Rev, 2015. 2015(9): p. CD008659. [cited by applicant]
Nunamaker et al, “Evaluation of Analgesic Efficacy of Meloxicam and 2 Formulations of Buprenorphine After Laparotomy in Female Sprague Dawley Rats”, Journal of the American Assoc for Laboratory Animal Science, 57(5): 49… [cited by applicant]
Vaughn, B. et al., Abstract for P-104, Efficacy and Safety of Meloxicam Co-Crystal and a Rapid-Absorption Formation of Meloxicam in the treatment of Post-Surgical Dental Pain, PainWeek 2024. [cited by applicant]
PainWeek 2024, Bertoch, Abstract for SAP-05, SAP-05—(Scientific Abstract Poster Live Presentation) Efficacy and Safety of Meloxicam Co-Crystal and a Rapid-Absorption Formulation of Meloxicam in The Treatment of Post-Sur… [cited by applicant]
PainWeek 2025, Abstract for P-039, Efficacy and safety of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy; https://painweek2025.eventscribe.… [cited by applicant]
PainWeek 2025, Abstract for P-041, Pharmacokinetics study comparing MR-107A-02 (novel fast-acting meloxicam formulation) 15mg tablet with meloxicam (Mobic®) 15mg in healthy adult male subjects; https://painweek2025.even… [cited by applicant]
PainWeek 2025, Abstract for P-076, Time to Efficacy Onset of MR-107A-02 (Novel Fast-Acting Meloxicam Formulation) in the Treatment of Acute Postoperative Pain Following Bunionectomy and Herniorrhaphy; https://painweek20… [cited by applicant]
PainWeek 2025, Abstract for P-40, Opioid sparing effect of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy and herniorrhaphy; https://painwe… [cited by applicant]
PainWeek 2025, Abstract for P-038, Efficacy and safety of MR-107A-02 (novel meloxicam fast-acting formulation) for the treatment of acute moderate-to-severe pain following herniorrhaphy; https://painweek2025.eventscribe… [cited by applicant]
Pollak, R.A., et al., Efficacy and Safety of Intravenous Meloxicam in Patients with Moderate-to-Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-controlled Trial. Clin J Pain, 2018. 34(10): p. 918… [cited by applicant]
PainWeek 2024 Poster #104 (Sep. 3-6, 2024, The Cosmopolitan of Las Vegas, Las Vegas, Nevada). [cited by applicant]
PainWeek 2025, Poster 38 (Sep. 2-5, 2025, The Cosmopolitan of Las Vegas, Las Vegas, Nevada). [cited by applicant]
PainWeek 2025, Poster 39 (Sep. 2-5, 2025, The Cosmopolitan of Las Vegas, Las Vegas, Nevada). [cited by applicant]
PainWeek 2025, Poster 40 (Sep. 2-5, 2025, The Cosmopolitan of Las Vegas, Las Vegas, Nevada). [cited by applicant]
PainWeek 2025, Poster 41 (Sep. 2-5, 2025, The Cosmopolitan of Las Vegas, Las Vegas, Nevada). [cited by applicant]
PainWeek 2025, Poster 76 (Sep. 2-5, 2025, The Cosmopolitan of Las Vegas, Las Vegas, Nevada). [cited by applicant]
QAMZOVA [package insert]. U.S. Food and Drug Administration. Revised [Apr. 2025]. Accessed Oct. 31, 2025. [cited by applicant]
Romer D (1980). Pharmacological evaluation of mild analgesics. Br J Clin Pharmacol, 10: 247S-251S. [cited by applicant]
Santos AR et al., Antinociceptive effect of meloxicam, in neurogenic and inflammatory nociceptive models in mice. Inflam Res, (1998) 47(7):302-307. [cited by applicant]
Small, C. and Laycock, H., Acute postoperative pain management. Br J Surg, 2020. 107(2): p. e70-e80. [cited by applicant]
Tubbs et al., “Effects of Buprenorphine, Meloxicam, and Flunixin Meglumine as Postoperative Analgesia in Mice” Journal American Assoc Lab Animal Sci, 2:185-191, (2011). [cited by applicant]
U.S. Centers for Disease Control and Prevention, CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths. Released 2025. Accessed Oct. 15, 2025. Available at https://www.cdc.gov/media/releases/2025/2025-cdc-reports-… [cited by applicant]
Viatris Aug. 1, 2025 Press Release, “Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PainWeek 2025 Conference”, https://newsroom.viatris.com/2025-08-01-Viatris-Announces-Five-Dat… [cited by applicant]
Viatris May 8, 2025 Press Release, Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain, https://new… [cited by applicant]
XIFYRM [package insert]. U.S. Food and Drug Administration. Revised [Jun. 2025]. Accessed Oct. 31, 2025. [cited by applicant]
Yocum et al. “Archives of Internal Medicine”, 2000, 160(19):2947-5954. [cited by applicant]